A multicentre, open study assessing joint disorders Under ARIMIDEX [anastrozole] (1mg/Day) as adjuvant treatment in post menopausal women with early breast cancer.

Trial Profile

A multicentre, open study assessing joint disorders Under ARIMIDEX [anastrozole] (1mg/Day) as adjuvant treatment in post menopausal women with early breast cancer.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2012

At a glance

  • Drugs Anastrozole (Primary)
  • Indications Early breast cancer
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Apr 2012 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 05 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top